Human papillomavirus (HPV) remains the most prevalent sexually transmitted infection in the United States (U.S.). By the age of 45, over 80% of Americans will contract HPV, which creates a significant public health concern. Despite the availability of effective vaccines, low vaccination uptake continues to be a challenge, particularly in Tennessee. Additionally, the Advisory Committee on Immunization Practices (ACIP) recently expanded recommendations for HPV vaccine usage to include adults aged 27-45, suggesting a population with the potential to experience a gap in preventative care. To understand the underlying factors that may hinder Tennesseans from receiving the HPV vaccine, we conducted a cross-sectional survey from 29 June to 17 August 2023 among adults aged 18 to 45 in Tennessee. The survey was developed and informed by a scoping review regarding the various constructs and frameworks used in vaccine hesitancy and our previous qualitative work. Using theory-based instruments and previous qualitative data, this study aimed to determine the underlying factors that may hinder Tennesseans from receiving the HPV vaccine, focusing on those adults within the recently approved age range of 27-45 years old. An Exploratory Factor Analysis of 2011 participants ultimately included five factors, which explain 70.3% of the variability. These were Benefits/Trust, Perceived Susceptibility, Attitude/Behavioral Control, Perceived Barriers, and Perceived Severity. All Cronbach alphas were greater than 0.80, indicating that each factor was reliable. When stratifying by various demographics, our analysis found that race emerged as a significant factor ( = 0.002), while the interaction of race and vaccination status was not significant ( = 0.753). Black respondents had significantly lower levels of Benefits/Trust than White ( < 0.001) and Asian respondents ( = 0.030), with no significant differences between White and Asian respondents. These findings underscore the importance of researchers, healthcare professionals, public health officials, and policymakers in addressing these demographic differences to effectively increase vaccination rates and reduce HPV-associated cancer risks in Tennessee. Further studies are needed for targeted interventions to address these disparities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680357PMC
http://dx.doi.org/10.3390/vaccines12121405DOI Listing

Publication Analysis

Top Keywords

hpv vaccine
16
human papillomavirus
8
papillomavirus hpv
8
exploratory factor
8
factor analysis
8
public health
8
adults aged
8
underlying factors
8
factors hinder
8
hinder tennesseans
8

Similar Publications

Cervical cancer is the leading cause of cancer-related death among Latin American women, including Guatemalans. This is troubling, given we have a vaccine, screening tool, and treatment for this preventable disease. Human papillomavirus (HPV) causes most cervical cancer.

View Article and Find Full Text PDF

Aims: In people living with human immune deficiency (PLHIV), the rates of human papillomavirus (HPV) infection, mixed types, and high-risk (HR) strains increase, while the virus clearance is prevented. Here, we report HPV genotyping in PLHIVs from Iran and the Middle East region for the first time.

Methods: HPV genotyping in referring individuals from different provinces to our laboratory was evaluated over 2023-2024.

View Article and Find Full Text PDF

Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16-26 years from studies 001 (NCT00543543), 002 (NCT00943722), 003 (NCT01651949), and 020 (NCT02114385). Covariates considered were age, gender, sexual orientation, region of residence, and race.

View Article and Find Full Text PDF

Introduction Studies assessing human papillomavirus (HPV) vaccination uptake in survivors of childhood, adolescent, and young adult (CAYA) cancers are sparse. We examined HPV vaccine uptake between survivors of CAYA cancer aged 18-35 and 18-35-year-old respondents without a cancer diagnosis in the United States. Methods We used the 2017-2018 National Health Interview Survey, a national, annual cross-sectional national dataset that monitors health-related information on the non-institutionalized civilian population in the United States.

View Article and Find Full Text PDF

Objective: The incidence of human papillomavirus (HPV)-related oropharyngeal cancers has increased such that they are now the most prevalent HPV-related cancer. In 2020, the Food and Drug Administration (FDA) expanded the indication for Gardasil-9 to include the prevention of oropharyngeal and other head and neck cancers caused by selected HPV types, but uptake remains low. Otolaryngology office interactions may provide opportunities to increase uptake, given the relevance of HPV to clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!